Looking for a reliable and efficient way to predict the success of antiviral therapy and sustained virologic response (SVR) in your Hepatitis C Virus (HCV) infected patients? Look no further than the Viennalab IL28B RealFast™ Assay! Our assay accurately predicts the likelihood of HCV clearance by genotyping the functional variant rs368234815 TT>ΔG, providing a crucial tool for optimizing treatment decisions.

Direct-acting antivirals and pegylated Interferon/Ribavirin regimens are commonly used for the treatment of HCV infection. However, SVR is dependent on various factors, including virus genotype and patients’ age, sex, ethnicity, and genetic variants associated with antiviral activity. The functional variant rs368234815 TT>ΔG regulating IL28B expression is the strongest known host factor for predicting HCV clearance.

Genotyping of rs368234815 TT>ΔG using the Viennalab IL28B RealFast™ Assay helps to predict spontaneous and treatment-induced viral clearance in patients, independent of their ethnicity. Trust in our reliable and efficient assay to provide you with accurate and reliable results, enabling you to make informed treatment decisions for your patients. Order now and experience the convenience and efficiency of RealFast™ technology!